Related Experiment Video
Updated: Jan 31, 2026

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit
Published on: September 6, 2024
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future
Antoni Torres1,2,3,4, Anna Motos5, Denise Battaglini5,6
1Department of Pulmonary and Critical Care Medicine, Hospital Clinic, Calle Villarroel 170, Barcelona, 08036, Spain. atorres@clinic.ub.es.
Abstract:
Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
Insights
Nebulized antibiotics like amikacin in intensive care units show mixed results. This review analyzes evidence, discusses reasons for trial failures, and suggests improvements for future clinical trials.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Clinical Trials
Background:
- Nebulized antibiotics, particularly amikacin, are increasingly discussed for intensive care unit (ICU) use.
- Recent randomized clinical trials (RCTs) have yielded unconvincing results regarding efficacy.
Purpose of the Study:
- To critically examine and reappraise the evidence supporting and opposing nebulized antibiotic therapy in ICUs.
- To discuss potential factors contributing to the negative outcomes in recent clinical trials.
- To highlight underconsidered factors for improving future translational research and RCT design.
Main Methods:
- Systematic review and critical appraisal of existing evidence on nebulized antibiotics in ICUs.
- Analysis of factors influencing the outcomes of recent randomized clinical trials.
- Discussion of elements for enhancing future research and regulatory considerations.
Main Results:
- The evidence for and against nebulized amikacin in ICUs is complex and requires careful re-evaluation.
- Several factors, often overlooked, may explain the disappointing results of recent RCTs.
- There is a need to address specific considerations in study design and regulatory oversight.
Conclusions:
- Reappraisal of evidence suggests a need for nuanced understanding of nebulized antibiotic efficacy in ICUs.
- Addressing methodological and translational gaps is crucial for advancing research in this area.
- Improved future RCTs are essential to clarify the role of nebulized antibiotics in critical care.
More Related Videos
Related Concept Videos
Pulmonary Ventilation: Inhalation
Boyle's law becomes particularly pertinent when examining respiratory...
Gram-negative Bacterial Protein Secretion Systems
Measurement: Derived Units
Measurement: Standard Units
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Inhaled Medications

